構建表達人胃泌酸調節(jié)素的乳酸乳球菌及其治療肥胖的療效研究
發(fā)布時間：2018-07-18 11:40
【摘要】：肥胖是當今世界倍受關注的一個健康問題,世界衛(wèi)生組織(WHO)已經(jīng)將肥胖定義為一種疾病。肥胖人數(shù)在世界范圍內(nèi)一直呈現(xiàn)顯著上升的趨勢。肥胖不僅影響行動和生活質量,也與很多疾病有著密不可分的關系,如糖尿病、高血壓、心血管疾病、睡眠呼吸終止癥以及癌癥等等。導致肥胖的原因有很多,但高熱量食物導致的飲食結構改變是絕大多數(shù)肥胖產(chǎn)生的原因。胃泌酸調節(jié)素(OXM)是一種由腸上皮細胞分泌的肽類激素。人OXM含37個氨基酸殘基,具有抑制食欲和食物吸收、動員脂肪的作用。目前肽類作為藥物主要是通過化學合成或生物工程生產(chǎn),產(chǎn)品多為粉針劑,主要是通過注射的途徑給藥,成本高而且不方便。因此迫切需要一種載體系統(tǒng),能夠在人體內(nèi)穩(wěn)定表達OXM,并發(fā)揮其生物功能。乳酸乳球菌是益生菌,長期存在于腸道內(nèi),并且被認為是安全的(GRAS generally recognized as safe)[1]。目前已經(jīng)有相當多的文獻將乳酸乳球菌作為基因工程受體菌用于治療腸道炎癥[2]。我們利用基因工程的方法在乳酸乳球菌中表達人OXM,希望在人體腸道中穩(wěn)定,持續(xù)地表達OXM,使其能夠成為一種新型的藥物來治療肥胖癥。為了驗證這一假設,本論文構建了表達人OXM的乳酸乳球菌NZ3900,命名為NZ3900-OXM,同時通過Western blot等方法鑒定了菌株中OXM的表達,結果顯示NZ3900-OXM能夠穩(wěn)定表達OXM并將其分泌至培養(yǎng)基中。隨后,我們通過45%的高脂飲食構建了飲食誘導肥胖小鼠模型,將造模成功的肥胖小鼠分為兩組,分別灌胃表達OXM的乳酸乳球菌和對照菌株,觀察表達OXM的乳酸乳球菌對飲食誘導肥胖小鼠的體重、體脂、血糖、血脂和進食量等指標的影響。結果發(fā)現(xiàn),灌胃表達OXM的乳酸乳球菌8周后,飲食誘導肥胖小鼠的體重顯著下降至與普通飲食對照小鼠相一致,而且體脂和血脂也顯著下降。有趣的是,灌胃對照乳酸菌后肥胖小鼠的血糖也顯著下降,提示乳酸菌本身就足以使血糖的下降,但只有表達OXM的乳酸乳球菌才能夠顯著降低飲食誘導肥胖小鼠的體重、體脂和血脂。我們進一步在db/db小鼠上進行了驗證。結果發(fā)現(xiàn),經(jīng)過三周的灌胃給藥,NZ3900-OXM組的糖尿病小鼠的體重得到了很好的控制,而且糖化血紅蛋白含量、血脂含量顯著下降。本論文通過以上研究,旨在通過構建表達人胃泌酸調節(jié)素的乳酸乳球菌,有效地降低小鼠進食量、緩解二型糖尿病癥狀,從而為更安全、方便地治療肥胖癥和二型糖尿病找到一種可能的新型口服藥物,并值得進一步開發(fā)和完善。
[Abstract]:Obesity is a major concern in the world today. The WHO (WHO) has defined obesity as a disease. The number of obesity has been increasing worldwide. Obesity not only affects the quality of action and life, but also has a close relationship with many diseases, such as diabetes, hypertension, and cardiovascular disease. Disease, sleep apnea and cancer and so on. There are many causes of obesity, but the diet structure changes caused by high calorie foods are the cause of most obesity. OXM is a peptide hormone secreted by intestinal epithelial cells. Human OXM contains 37 amino acid residues, which can inhibit appetite and food absorption and activity. At present, the peptide as a drug is mainly produced by chemical synthesis or Bioengineering, and the products are mostly powder, mainly by injection, which is highly cost and inconvenient. Therefore, a carrier system is urgently needed to stabilize the expression of OXM in human body and play its biological function. Lactococcus lactis is a probiotic. GRAS generally recognized as safe [1]. is currently in the intestinal tract and is considered to be safe. There have been quite a lot of literature on the use of Lactococcus Lactococcus as gene engineering receptor bacteria for the treatment of intestinal inflammation [2].. We use genetic engineering to express human OXM in Lactococcus Lactobacillus in the hope of stabilizing the human intestinal tract. In order to verify this hypothesis, this paper constructs a NZ3900 Lactococcus lactis expressing human OXM, named NZ3900-OXM, and identified the expression of OXM in the strain by Western blot, and the results show that NZ3900-OXM can express OXM and secrete it to OXM in order to verify this hypothesis. In the medium. Then, we constructed a diet induced obesity mouse model by 45% high fat diet. The obese mice were divided into two groups, and the OXM Lactococcus Lactococcus and control strains were administered respectively. The weight, body fat, blood sugar, blood lipid and food intake of the OXM Lactococcus lactis in the diet induced obese rats were observed. The results showed that after 8 weeks of gavage of OXM Lactococcus lactis, the weight of the diet induced obese mice decreased significantly to the normal diet control mice, and the body fat and blood lipid decreased significantly. Interestingly, the blood sugar of the obese mice was also significantly decreased after the gavage of lactic acid bacteria, suggesting that lactic acid bacteria itself was sufficient to make blood sugar. But only OXM Lactococcus Lactococcus could significantly reduce the weight, body fat and blood lipid in the diet induced obese mice. We further tested the db/db mice. The results showed that after three weeks of gavage, the body weight of the diabetic mice in group NZ3900-OXM was well controlled and the glycated hemoglobin was contained. In this paper, the aim of this study is to establish a new type of possible new oral medicine for the treatment of obesity and type two diabetes by constructing the Lactococcus lactis expressing human Gastro secreting hormone, reducing the intake of mice and alleviating the symptoms of type two diabetes. Development and improvement.
【學位授予單位】：南京醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2015
【分類號】：R589.2
本文編號：2131793
[Abstract]:Obesity is a major concern in the world today. The WHO (WHO) has defined obesity as a disease. The number of obesity has been increasing worldwide. Obesity not only affects the quality of action and life, but also has a close relationship with many diseases, such as diabetes, hypertension, and cardiovascular disease. Disease, sleep apnea and cancer and so on. There are many causes of obesity, but the diet structure changes caused by high calorie foods are the cause of most obesity. OXM is a peptide hormone secreted by intestinal epithelial cells. Human OXM contains 37 amino acid residues, which can inhibit appetite and food absorption and activity. At present, the peptide as a drug is mainly produced by chemical synthesis or Bioengineering, and the products are mostly powder, mainly by injection, which is highly cost and inconvenient. Therefore, a carrier system is urgently needed to stabilize the expression of OXM in human body and play its biological function. Lactococcus lactis is a probiotic. GRAS generally recognized as safe [1]. is currently in the intestinal tract and is considered to be safe. There have been quite a lot of literature on the use of Lactococcus Lactococcus as gene engineering receptor bacteria for the treatment of intestinal inflammation [2].. We use genetic engineering to express human OXM in Lactococcus Lactobacillus in the hope of stabilizing the human intestinal tract. In order to verify this hypothesis, this paper constructs a NZ3900 Lactococcus lactis expressing human OXM, named NZ3900-OXM, and identified the expression of OXM in the strain by Western blot, and the results show that NZ3900-OXM can express OXM and secrete it to OXM in order to verify this hypothesis. In the medium. Then, we constructed a diet induced obesity mouse model by 45% high fat diet. The obese mice were divided into two groups, and the OXM Lactococcus Lactococcus and control strains were administered respectively. The weight, body fat, blood sugar, blood lipid and food intake of the OXM Lactococcus lactis in the diet induced obese rats were observed. The results showed that after 8 weeks of gavage of OXM Lactococcus lactis, the weight of the diet induced obese mice decreased significantly to the normal diet control mice, and the body fat and blood lipid decreased significantly. Interestingly, the blood sugar of the obese mice was also significantly decreased after the gavage of lactic acid bacteria, suggesting that lactic acid bacteria itself was sufficient to make blood sugar. But only OXM Lactococcus Lactococcus could significantly reduce the weight, body fat and blood lipid in the diet induced obese mice. We further tested the db/db mice. The results showed that after three weeks of gavage, the body weight of the diabetic mice in group NZ3900-OXM was well controlled and the glycated hemoglobin was contained. In this paper, the aim of this study is to establish a new type of possible new oral medicine for the treatment of obesity and type two diabetes by constructing the Lactococcus lactis expressing human Gastro secreting hormone, reducing the intake of mice and alleviating the symptoms of type two diabetes. Development and improvement.
【學位授予單位】：南京醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2015
【分類號】：R589.2
【相似文獻】
相關期刊論文 前1條
1 雷春濤;王志偉;文秀英;;胃泌酸調節(jié)素對體重及糖代謝影響的研究進展[J];中華臨床醫(yī)師雜志(電子版);2013年24期
相關重要報紙文章 前1條
1 ;英國研制出瘦身新法──“關閉”胃口[N];新華每日電訊;2005年
相關碩士學位論文 前1條
1 向榮;構建表達人胃泌酸調節(jié)素的乳酸乳球菌及其治療肥胖的療效研究[D];南京醫(yī)科大學;2015年
，本文編號：2131793
本文鏈接：http://sikaile.net/yixuelunwen/nfm/2131793.html
最近更新
教材專著
